Buy Lavasept solution 5 ml 1 pc.
  • Buy Lavasept solution 5 ml 1 pc.

Lavesept® [Polyhexanide]

Solupharm Pharmaceutical Ertsouignissse GmbH
1123 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$56.95
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

LAVACEPT - antiseptic drug.

Polyhexanide has a broad spectrum of antimicrobial action.

Active in relation to:
Gram-positive and gram-negative bacteria (including Pseudomonas aeruginosa).
Mushrooms.

Polyethylene glycol (PEG) reduces surface tension, which contributes to enhancing the action of polyhexanide.

In the presence of protein (0.2% albumin), the effect of the drug is weakened only slightly, and when conducting quantitative tests a good fungicidal and bactericidal effect is detected.

The drug does not contain substances that have an irritating effect: halogen and mercury-containing antiseptics, iodine, heavy metals, polyvinylpyrrolidone and aldehydes.

Polyhexanide is chemically stable, non-volatile, odorless, soluble in water, ethanol, glycerol, propylene glycol and other solvents.

Polyhexanide has a low toxicity, and the content of polyethylene glycol in Lavasept concentrate is low in order to enhance the toxicity of polyhexanide.

Indications

- antiseptic treatment in the surgical treatment of infected wounds and superficial soft tissue injuries;

- washing the cavities through the drainage tubes using active drainage;

- irrigation of the operative field during surgery during reconstructive operations, immediately prior to bone and soft tissue transplantation;

—The irrigation of the operational field during operations with the existing threat of infection;

—The treatment of infected wounds during the operation of a hip joint endoprosthesis (according to Schneider);

- Antiseptic protection of open wounds;

- treatment of burn surfaces;

—Antiseptic treatment during maxillofacial operations;

—Processing of surgical instruments, dressings and patient care items.

Composition

Polyhexanide

Excipients: water d / i, macrogol 400 (PEG) 10 mg

No customer reviews for the moment.

Write your review

Write your review

Lavesept® [Polyhexanide]

Dosage and Administration

Lavasept concentrate is used only externally. Before applying Laveapept concentrate should be diluted to a concentration of 0.1% or 0.2%.

For washing and drainage of wounds, a 0.1% solution of Lavasept concentrate should be used.

In the case of infection of the wounds with gram-negative flora, a 0.2% solution of the drug is used.

Rules of preparation of the solution

To prepare a 0.1% or 0.2% Lava-cept solution, 1000 ml of Ringer’s solution should be added with 1 ml or 2 ml of Lava-cept concentrate, respectively. When mixed with other solutions, turbidity and precipitation should be avoided. Polyhexanide precipitated at low temperatures can be dissolved by heating the solution to 60 ° C.

Adverse reactions

Allergic reactions: skin rash, urticaria.

Contraindications

- operations on uninfected joints;

- brain and spinal cord surgery (neurosurgical operations);

- operations on the middle and inner ear;

- eye operations (ophthalmologic operations);

- intraperitoneal washing;

- increased sensitivity to the components of the drug.

Drug interactions

Currently, cases of drug interactions are not known.

Pregnancy and Lactation

Currently, there is not enough data on the use of Laveasept concentrate during pregnancy and lactation. It is not recommended to use the drug in the first trimester of pregnancy. In later periods of pregnancy and lactation, use is possible only if the intended benefit to the mother exceeds the possible risk to the fetus or child.

Special instructions

  • If an allergic reaction occurs, the use of Lava-cepta concentrate should be immediately stopped and anti-allergic therapy (antihistamine medication) should be prescribed.
  • When using Laveapept concentrate, it is necessary to avoid its delay in the tissues.
  • In experimental animal studies, it was shown that Lavasept concentrate inhibits the growth of embryonic cartilage tissue. With long-term use, Laveasept can damage intact cartilage. Therefore, do not use Lavasept concentrate for washing uninfected joints. In case of accidental ingestion of the drug on intact cartilage tissue during an operation on an uninfected joint, the entire joint should be washed with Ringer's solution or saline.
  • When using Lavasepta concentrate on inflamed and infected joints, with significant lesions, in cases when arthrodesis or total joint replacement is planned, Lavasept concentrate can create an optimal level of disinfection, providing a favorable outcome of the operation.
  • Use in Pediatrics
  • In pediatric practice, a 0.1% solution of Lavasept concentrate is used. Due to the lack of experience with the use of Lavasepta concentrate in children under 3 years of age, the use of the drug in patients of this age group is possible only after a thorough assessment of the risk-benefit ratio.

Overdosage

Cases of overdose are not described.

  • Brand name: Lavasept
  • Active ingredient: Polyhexanide
  • Dosage form: Concentrate for preparation of solution for external use
  • Manufacturer: Solupharm Pharmaceutical Ertsouignissse GmbH
  • Country of Origin: Germany

Studies and clinical trials of Polyhexanide (Click to expand)
  1. Severe anaphylaxis to the antiseptic polyhexanide
  2. Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis
  3. Clinical comparison of three polyhexanide-preserved multi-purpose contact lens solutions
  4. Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns
  5. Effect of a combination of a propyl-betaine and polyhexanide containing irrigation solution on methicillin resistant Staphylococcus aureus (MRSA) biofilms in porcine model
  6. In-vitro analysis of the effect of gentamicin and polyhexanide on bone tissue
  7. In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus
  8. Activity of the antiseptic polyhexanide against meticillin-susceptible and meticillin-resistant Staphylococcus aureus
  9. Albumin reduces the antibacterial activity of polyhexanide-biguanide-based antiseptics against Staphylococcus aureus and MRSA
  10. Exit-Site Infection of Peritoneal Catheter is Reduced by the Use of Polyhexanide. Results of a Prospective Randomized Trial
  11. Polyhexanide-containing solution reduces ciliary beat frequency of human nasal epithelial cells in vitro
  12. Enzyme Responsive Hyaluronic Acid Nanocapsules Containing Polyhexanide and Their Exposure to Bacteria To Prevent Infection
  13. Polyhexanide anti-infective coating of central venous catheters in prevention of catheter colonization and bloodstream infection: Study HC-G-H-0507
  14. Activity of the Antiseptic Polyhexanide Against Gram-Negative Bacteria
  15. Antisepsis with polyhexanide is effective against endophthalmitis after intravitreal injections
  16. Cytokine Expression in Human Osteoblasts After Antiseptic Treatment: A Comparative Study Between Polyhexanide and Chlorhexidine
  17. Clinical Safety and Efficacy of a Novel Thermoreversible Polyhexanide-Preserved Wound Covering Gel
  18. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate
  19. A cohort study on the efficacy of a polyhexanide-containing biocellulose dressing in the treatment of biofilms in wounds
  20. Influence of the Antiseptic Agents Polyhexanide and Octenidine on FL Cells and on Healing of Experimental Superficial Aseptic Wounds in Piglets
  21. Photodynamic Inactivation of Actinomyces naeslundii in Comparison With Chlorhexidine and Polyhexanide—A New Approach for Antiseptic Treatment of Medication-Related Osteonecrosis of the Jaw?
  22. Randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy of polyhexanide for topical decolonization of MRSA carriers
  23. Polyhexanide and hydrogen peroxide inhibit proteoglycan synthesis of human chondrocytes
  24. Reducing the pathogen burden and promoting healing with polyhexanide in non-healing wounds: a prospective study

8 other products in the same category:

arrow_upward